Manuel Banzhaf

Dr. Manuel Banzhaf


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2011 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
ATAthanasios Typas
Athanasios Typas
MBManuel Banzhaf
Manuel Banzhaf
CGCarol A. Gross
Carol A. Gross
WVWaldemar Vollmer
Waldemar Vollmer

1 December 2010 in Cell
Verified
Journal Article
Open access
ATAthanasios Typas
Athanasios Typas
MBManuel Banzhaf
Manuel Banzhaf
BSBart van Den Berg van Saparoea
Bart van Den Berg van Saparoea
JVJolanda Verheul
Jolanda Verheul
JBJacob Biboy
Jacob Biboy
WVWaldemar Vollmer
Waldemar Vollmer
Growth of the mesh-like peptidoglycan (PG) sacculus located between the bacterial inner and outer membranes (OM) is tightly regulated to ensure cellular integrity, maintain cell shape, and orchestrate division. Cytoskeletal elements direct placement and activity of PG synthases from inside the cell, but precise spatiotemporal control over this process is poorly understood. We demonstrate that PG synthases are also controlled from outside of the sacculus. Two OM lipoproteins, LpoA and LpoB, are essential for the function, respectively, of PBP1A and PBP1B, the major E. coli bifunctional PG synthases. Each Lpo protein binds specifically to its cognate PBP and stimulates its transpeptidase activity, thereby facilitating attachment of new PG to the sacculus. LpoB shows partial septal localization, and our data suggest that the LpoB-PBP1B complex contributes to OM constriction during cell division. LpoA/LpoB and their PBP-docking regions are restricted to γ-proteobacteria, providing models for niche-specific regulation of sacculus growth.

4 July 2018 in Nature
Verified
Journal Article
Open access
PDF file
ABAna Rita Brochado
Ana Rita Brochado
ATAnja Telzerow
Anja Telzerow
JBJacob Bobonis
Jacob Bobonis
MBManuel Banzhaf
Manuel Banzhaf
AMAndré Mateus
André Mateus
ATAthanasios Typas
Athanasios Typas
The spread of antimicrobial resistance has become a serious public health concern, making once-treatable diseases deadly again and undermining the achievements of modern medicine1,2. Drug combinations can help to fight multi-drug-resistant bacterial infections, yet they are largely unexplored and rarely used in clinics. Here we profile almost 3,000 dose-resolved combinations of antibiotics, human-targeted drugs and food additives in six strains from three Gram-negative pathogens—Escherichia coli, Salmonella enterica serovar Typhimurium and Pseudomonas aeruginosa—to identify general principles for antibacterial drug combinations and understand their potential. Despite the phylogenetic relatedness of the three species, more than 70% of the drug–drug interactions that we detected are species-specific and 20% display strain specificity, revealing a large potential for narrow-spectrum therapies. Overall, antagonisms are more common than synergies and occur almost exclusively between drugs that target different cellular processes, whereas synergies are more conserved and are enriched in drugs that target the same process. We provide mechanistic insights into this dichotomy and further dissect the interactions of the food additive vanillin. Finally, we demonstrate that several synergies are effective against multi-drug-resistant clinical isolates in vitro and during infections of the larvae of the greater wax moth Galleria mellonella, with one reverting resistance to the last-resort antibiotic colistin.

28 June 2013 in Science
Verified
Journal Article
Closed access
PDF file
BEBenjamin Ezraty
Benjamin Ezraty
AVAlexandra Vergnes
Alexandra Vergnes
MBManuel Banzhaf
Manuel Banzhaf
YDYohann Duverger
Yohann Duverger
AHAllison Huguenot
Allison Huguenot
FBFrédéric Barras
Frédéric Barras
Unreactive Death: A controversial proposal that all bactericidal antibiotics kill by reactive oxygen species (ROS) and not by their primary cell target has recently attracted high-profile refutations. The ROS-death pathway implicated overstimulation of the electron transport in respiratory chains; a malfunction that leads to ROS releasing Fe from Fe-S clusters and causing cell death via Fenton chemistry. Ezraty et al. (p. 1583 ) show that electron transport chains and Fe-S clusters are key to killing by aminoglycoside antibiotics but not for the reasons envisioned in the ROS theory. Fe-S clusters are essential for killing because they mature the respiratory chains that produce the necessary proton motive force for the energized uptake of aminoglycosides. Consequently, iron chelators protect against aminoglycosides, not because they scavenge the iron from Fenton chemistry, but because they block aminoglycoside uptake.

21 May 2012 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
MBManuel Banzhaf
Manuel Banzhaf
BSBart van Den Berg van Saparoea
Bart van Den Berg van Saparoea
MTMohammed Terrak
Mohammed Terrak
CFClaudine Fraipont
Claudine Fraipont
AEAlexander Egan
Alexander Egan
WVWaldemar Vollmer
Waldemar Vollmer
Summary: Growth of the bacterial cell wall peptidoglycan sacculus requires the co‐ordinated activities of peptidoglycan synthases, hydrolases and cell morphogenesis proteins, but the details of these interactions are largely unknown. We now show that the Escherichia coli peptidoglycan glycosyltrasferase‐transpeptidase PBP1A interacts with the cell elongation‐specific transpeptidase PBP2 in vitro and in the cell. Cells lacking PBP1A are thinner and initiate cell division later in the cell cycle. PBP1A localizes mainly to the cylindrical wall of the cell, supporting its role in cell elongation. Our in vitro peptidoglycan synthesis assays provide novel insights into the cooperativity of peptidoglycan synthases with different activities. PBP2 stimulates the glycosyltransferase activity of PBP1A, and PBP1A and PBP2 cooperate to attach newly synthesized peptidoglycan to sacculi. PBP2 has peptidoglycan transpeptidase activity in the presence of active PBP1A. Our data also provide a possible explanation for the depletion of lipid II precursors in penicillin‐treated cells.

1 December 2014 in Cell
Verified
Journal Article
Closed access
SCSeung-Hyun Cho
Seung-Hyun Cho
JSJoanna Szewczyk
Joanna Szewczyk
CPChristina Pesavento
Christina Pesavento
MZMatylda Zietek
Matylda Zietek
MBManuel Banzhaf
Manuel Banzhaf
JCJean-François Collet
Jean-François Collet